Virtual reality mental and behavioral health companies BehaVR (Nashville, TN-based), and OxfordVR (Oxford, UK-based) merged and raised $13M in Series B funding.
The round was led by Optum Ventures and Oxford Science Enterprises, with participation from Confluent Health, Accenture Ventures, Chrysalis Ventures and Thornton Capital.
The combined company will operate under the BehaVR brand.
Led by CEO Aaron Gani, the company builds evidence-based, immersive, digital therapeutics. Its suite of clinically validated therapeutics offer access to treatments on a spectrum across mental wellness and mental and behavioral conditions, including validated treatments for serious mental illness. The company delivers these treatments on an integrated platform that simplifies the patient experience, enables clinician oversight, and generates patient-specific care plans and measurable outcomes.
OxfordVR, whose gameChange product was recently granted FDA Breakthrough Device designation, will treat patients using automated cognitive-behavioral VR therapy. These therapies can be delivered by a wide range of clinical staff, peer group members and at home.
FinSMEs
14/12/2022